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Actin is a protein found in the cytoskeleton that aids in movement and building in cells
(Figure 1). Actin related protein 2/3 (Arp2/3) complex is a structural protein that is
involved in the branching of actin (Figure 2).1 It has been found that Arp2/3 complex is
involved in instances of cancer metastasis. Tumor cells utilize the function of Arp 2/3
complex to move and proliferate.2 Small molecules are being looked at as inhibitors
for Arp2/3 complex. One breakthrough study identified two structural classes of
inhibitors via high-throughput screening.3
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4-thiazolidinones are being researched in order to increase 
inhibition. For this class of molecules, insight on optimal 
conditions for synthesis is being researched to increase yield 
and purity of the small molecules. This is important knowledge 
to gain as the potential applications are impactful. High 
potency is desirable so the molecules would be useful as 
research tools in the basic science of actin dynamics and 
potentially useful to interfere with cancer cell metastasis. 
Figure 1: 
Branching actin 
filaments in the 
cytoskeleton of 
a cell
Figure 2: Method of Arp2/3 complex function
In general, to synthesize the molecules a mixture of aldehyde (1.0 equiv.) and amine 
(2.0 equiv.) were combined with tetrahydrofuran (THF) for fifteen minutes in ice cold 
conditions. Mercapto acetic acid (3.0 equiv.) was added and allowed to mix for five 
minutes. DCC (1.2 equiv.) was mixed at room temperature for fifty minutes.4 
Compounds were purified by column chromatography.
The next immediate step for this scaffold of 4-
thazolidinones is to conduct biochemical 
assays that give results on inhibitor strength, 
IC50 values.
7 The goal is to increase potency by 
two to three orders of magnitude. An increase 
of potency would create a molecule of high 
interest for basic actin research and potential 
clinical anticancer applications. 
The more molecules that get results, positive or 
negative, in the assays allow for more insight 
into what new molecules that should be 
synthesized. Dr. Zoe Cournia will perform 
computational docking to help us gain an idea 
of possible molecules to test based off of earlier 
results. Use of this iterative process is well 
established in the pharmaceutical industry in 
the development of first-in-class drugs.
Figure 11: Gemini XPS microplate reader 
used for biochemical assays and outline of 
assay components
Synthesis methods that use different peptide coupling agents other than DCC 
have been found to show promise of better results.5 Peptide coupling reagents 
such as HBTU, PyBOP, and others could be utilized to see how the results 
compare to DCC. 
Only one enantiomer of CK-869 is thought to be an active inhibitor.6 In order to 
separate the R and S enantiomers, chiral HPLC could be utilized (Figure 9). 
Addition of a thiol at the R1 position could result in the creation of a sulfur-sulfur 
bridge between the R1 position and cysteine 12. Also, alkyl groups added to the 
R1 substituent, and a larger range of substituents including longer chains on the 
R2 substituent are of interest (Figure 10).
Figure 8: The structures of the five molecules synthesized along with the reported yields
Figure 6: A general 
synthesis outline for 
the CK-869 Scaffold 
Figure 7: Mechanism 
for 4-thiazolidinones 
from peptide 
coupling. R1 and R2
are substituents we 
are interested in 
changing 
Figure 5: Derivatives of CK-869 shown to have 
anticancer activity. Potency against A549 human lung 
cancer cell line, from substituent alterations in CK-869
Key Project Goals:
• Explore more structural 
modifications to CK-869 to 
increase potency
• Explore the mechanism 
connecting CK-869 and cancer 
metastasis (role of Arp2/3) 
Figure 9: Separation of R and S enantiomers by using 
chiral HPLC
Figure 10: Substituents of interest to change
Figure 3: The binding site of CK-869 
in Arp2/3 complex
Figure 4: CK-869 (yellow oval) disturbing the sensor 
loop of Arp3, thus destabilizing the active conformation
